{"id":"NCT03090191","sponsor":"Pfizer","briefTitle":"Clostridium Difficile Vaccine Efficacy Trial","officialTitle":"A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-03-29","primaryCompletion":"2021-12-21","completion":"2021-12-21","firstPosted":"2017-03-24","resultsPosted":"2023-02-13","lastUpdate":"2023-02-13"},"enrollment":17535,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Clostridium Difficile Infection"],"interventions":[{"type":"BIOLOGICAL","name":"Clostridium difficile vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Clostridium difficile vaccine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The Clover trial is evaluating an investigational vaccine that may help to prevent Clostridium difficile infection. Participants in the study are adults 50 years of age and older, who are at risk of developing Clostridium difficile infection. The study will assess whether the vaccine prevents the disease, and whether it is safe and well tolerated.\n\nEach subject will receive 3 doses of Clostridium difficile vaccine or placebo and be followed for up to 3 years after vaccination for potential Clostridium difficile infection.","primaryOutcome":{"measure":"Number of First Primary Episodes of Clostridium Difficile Infection (CDI) (Definition 1) Follow-up After Dose 3","timeFrame":"From 14 days after Dose 3 to the end of the surveillance period (mean follow-up after dose 3 was 34.2 months)","effectByArm":[{"arm":"Clostridium Difficile Vaccine","deltaMin":17,"sd":null},{"arm":"Placebo","deltaMin":25,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":13},"locations":{"siteCount":426,"countries":["United States","Argentina","Australia","Belgium","Bulgaria","Canada","Chile","Colombia","Czechia","Finland","France","Germany","Hungary","Japan","Peru","Poland","Portugal","Slovakia","South Korea","Spain","Sweden","Taiwan","United Kingdom"]},"refs":{"pmids":["39180325"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=B5091007"]},"adverseEventsSummary":{"seriousAny":{"events":719,"n":8722},"commonTop":["Fatigue (FATIGUE)","Headache (HEADACHE)","Injection site pain (PAIN)","Myalgia (MUSCLE PAIN)","Arthralgia (JOINT PAIN)"]}}